Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1844 of 6351
-
Spine surgery breakthrough? bone marrow clot may speed up fusion
Disease control OngoingSpinal fusion (SF) is a common orthopedic procedure to treat spinal diseases. Apart from fixation systems, the procedure requires bone grafting to further improve SF. Cell-based therapies as vertebral bone marrow aspirate (vBMA) with bone allograft were developed as alternative t…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug may scratch the itch for dialysis patients
Symptom relief CompletedThis a multicentre study that consists of a 12-week double-blind period, and an optional 14-week open-label extension period and a 1-week follow-up period.
Phase 3 • Sponsor: Vifor Fresenius Medical Care Renal Pharma • Aim: Symptom relief
Last updated Jun 26, 2026 15:36 UTC
-
Blood test breakthrough? new study hopes to sniff out liver cancer early.
Diagnosis Recruiting nowHIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma a…
Sponsor: Epiliquid Holding, Inc • Aim: Diagnosis
Last updated Jun 26, 2026 14:28 UTC
-
New drug combo aims to control CLL/SLL in early treatment
Disease control OngoingThis phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow an…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug duo targets tough lung cancer in early trial
Disease control OngoingThe purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect …
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
AI-Powered daily radiation adjustments aim to improve anal cancer treatment
Disease control Recruiting nowThis is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer. The tumor and a patient's anatomy may change during radiation treatment and daily adaption of the radiation plan (i.e., a…
Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New Triple-Drug cocktail aims to tackle tough breast cancer
Disease control Recruiting nowThis phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to o…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug targets urgent bathroom needs in colitis patients
Disease control CompletedA study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail shows promise for Late-Stage colon cancer
Disease control Recruiting nowThis study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin…
Phase 2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy aims to halt rapid heart disease progression in inflamed arteries
Disease control Recruiting nowThis is a self-controlled cohort study to evaluate the efficacy and safety of comprehensive treatment in patients with inflammation-associated rapidly-progressive coronary artery disease (IR-CAD) by comparing the study endpoints before treatment with those after treatment in the …
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Shorter treatment course may ease side effects for AML patients
Disease control OngoingAcute myeloid leukemia (AML): continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cycle = standard of care for intensive induction therapy ineligible AML patients in Germany The VENAZA-5S pilot trial: AZA administration reduced to 5 days within each …
Phase 2 • Sponsor: University of Leipzig • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can a single injection silence a clotting protein and prevent strokes?
Disease control OngoingThe purpose of this study is to evaluate safety, tolerability, PK, and PD of SAD of FXI-GalNAc-siRNA administered SC to healthy subjects.
Phase 1 • Sponsor: Sirnaomics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug shows promise for nasal polyps in chinese patients
Disease control CompletedThis is a parallel group, Phase 3, 2-arm study for treatment. The purpose of this study is to evaluate dupilumab subcutaneous (SC) injections compared to placebo in Chinese adult participants with CRSwNP, on a background therapy with intranasal corticosteroids (budesonide nasal s…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for esophageal cancer: drug cocktail trial launches
Disease control Recruiting nowThis is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carci…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New triple therapy may finally knock out tough stomach bug
Disease control CompletedDual therapy containing vonoprazan and amoxicillin had showed excellent eradication results with Helicobacter pylori first-line treatment. However, no study has examined its efficacy for H. pylori rescue treatment. Rifabutin has low antibiotic resistance, superior antibacterial a…
Phase 4 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 26, 2026 17:06 UTC
-
AI cameras vs. panic buttons: which saves seniors faster after a fall?
Disease control Recruiting nowMaintaining the elderly at home and preventing them from falling are major public health issues. The vast majority of elderly people wish to remain at home. The fear of a fall with prolonged standing is a frequent reason for institutionalization. There are few procedures that hav…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 26, 2026 14:24 UTC
-
Shingles vaccine put to the test in frail patients
Prevention Recruiting nowHerpes zoster (HZ) is a serious health problem whose incidence and severity increase with the decline of cell-mediated immunity (CMI) because of age and immunocompromised (IC) status. Subclinical reactivation are described and may boost the adaptive specific immunity. T cells pla…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Prevention
Last updated Jun 27, 2026 09:11 UTC
-
New eye drug shows promise for diabetic vision loss
Disease control CompletedThe purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.
Phase 2 • Sponsor: Greater Houston Retina Research • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Phone app uses GPS to fight opioid relapse
Disease control By invitation onlyThe proposed clinical trial would evaluate the use of smartphone applications ("apps", which have well-established efficacy in reducing cigarette and alcohol use) to prevent relapse among patients receiving medication-assisted treatment for opioid use disorder. In addition to sta…
Sponsor: University of Arkansas • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for brain tumors: drug targets genetic weakness
Disease control Recruiting nowBackground: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed. Objective: To see if a study drug (zotiraciclib) is effective in peo…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC